An new study shows that transcatheter aortic valve-in-valve implantation may be an important option for a growing population of patients with deteriorating bioprosthetic implants, but outcomes depend strongly on how the previous valve is failed.
New research released this week provides more support for the use of transcatheter aortic valve-in-valve (VIV) implantation as a means of replacing previously implanted valves that have deteriorated over time.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1waOj6J
Cap comentari:
Publica un comentari a l'entrada